Akebia Therapeutics (AKBA) Operating Margin (2017 - 2025)
Akebia Therapeutics (AKBA) has disclosed Operating Margin for 9 consecutive years, with 14.84% as the latest value for Q4 2025.
- On a quarterly basis, Operating Margin rose 1592.0% to 14.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.95%, a 4146.0% increase, with the full-year FY2025 number at 9.95%, up 4146.0% from a year prior.
- Operating Margin was 14.84% for Q4 2025 at Akebia Therapeutics, down from 7.57% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 23.57% in Q1 2025 to a low of 149.95% in Q2 2021.
- A 5-year average of 46.34% and a median of 30.89% in 2023 define the central range for Operating Margin.
- Biggest YoY gain for Operating Margin was 27473bps in 2021; the steepest drop was -5733bps in 2021.
- Akebia Therapeutics' Operating Margin stood at 113.28% in 2021, then soared by 97bps to 2.94% in 2022, then surged by 183bps to 2.45% in 2023, then tumbled by -1358bps to 30.77% in 2024, then surged by 52bps to 14.84% in 2025.
- Per Business Quant, the three most recent readings for AKBA's Operating Margin are 14.84% (Q4 2025), 7.57% (Q3 2025), and 22.55% (Q2 2025).